Benzinga | Jan 11, 2022 08:18AM EST

Fusion Pharmaceuticals Announces Research Collaboration With Pepscan tT Develop Peptide-Based Radiopharmaceuticals; Fusion Will Have Global Rights To Develop And Commercialize Any Peptides Discovered Under Collaboration

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the company has entered into a strategic research collaboration with Pepscan Therapeutics B.V. (Pepscan) to discover novel, peptide-based radiopharmaceuticals for the treatment of various solid tumors.

"Fusion's internal research and develop capabilities combined with expertise in radiopharmaceuticals allow us to create novel targeted alpha therapies (TATs) using a variety of classes of targeting molecules, including antibodies, small molecules and peptides -- all of which have been used successfully in radiopharmaceutical development," said Fusion Chief Executive Officer John Valliant, Ph.D. "We are pleased to work with Pepscan who has a proprietary platform for peptide discovery that will enable us to create novel, peptide-based targeted alpha therapies (TATs), further augementing our pipeline of radiopharmaceuticals."

Under the agreement, Fusion has global rights to develop and commercialize any peptides discovered under the collaboration.